ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "risk factors"

  • Abstract Number: 0242 • ACR Convergence 2020

    Autoantibody Profile and Ethnicity: Risk Factors for Accelerated Development of Lupus Nephritis

    Majed Albirdisi1, David d'Cruz2, Shirish Sangle2 and Natasha Jordan3, 1King Fahad Medical City, riyadh, Saudi Arabia, 2guys and st thomas hospital, london, United Kingdom, 3addebrooke's hospital, cambridge, United Kingdom

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease. African ancestry is associated with an increased risk of Lupus Nephritis (LN). Anti-DNA autoantibodies play…
  • Abstract Number: 0829 • ACR Convergence 2020

    International Comparison of Japanese and US Cross Country Utilization of RA Medications

    Hisashi Yamanaka1, Mitsumasa Kishimoto2, Kazuhisa Nakano3, Kenta Misaki4, Yuji Yamanishi5, Hiroaki Dobashi6, Masamitsu Natsumeda7, Toshiaki Miyamoto8, Koichi Amano9, Akira Sagawa10, Norihiko Koido11, Corrona Japan Consortium12, Leslie Harrold13, Tin-chi Lin13, Jeffrey Greenberg14 and Yoshiya Tanaka3, 1Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, 2Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 3The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 4Kitaharima Medical Center, Ono, Japan, 5Hiroshima Rheumatology Clinic, Hiroshima, Japan, 6Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 7Mabi Memorial Hospital, Kurashiki, Japan, 8Seirei Hamamatsu General Hospital, Hamamatsu, Japan, 9Saitama Medical Center, Kawagoe, Japan, 10Sagawa Akira Rheumatology Clinic, Sapporo, Japan, 11Kawasaki RA & IM Clinic, Kawasaki, Japan, 12Corrona Japan Consortium, Japan, Japan, 13Corrona, LLC, Waltham, MA, 14Corrona, LLC and NYU School of Medicine, Waltham, MA

    Background/Purpose: Little is known regarding differences in DMARD utilization across countries. A better understanding is needed to contextualize findings from different countries.1 Using the same…
  • Abstract Number: 1360 • ACR Convergence 2020

    New-Onset Inflammatory Bowel Diseases Among IL-17 Inhibitors-Treated Patients: Results from the Case-Control MISSIL Study

    Jean-Guillaume Letarouilly1, Benjamin Pariente2, Thao Pham3, Emilie Acquacalda4, Béatrice Banneville5, Sébastien Barbarot6, Elodie Bauer7, Pauline Baudart8, Pascal Claudepierre9, Arnaud Constantin10, Emmanuelle Dernis11, Renaud Felten12, Philippe Gaudin13, Céline Girard14, Bruno Gombert15, Philippe Goupille16, Xavier Guennoc17, Isabelle Henry-Desailly18, Denis Jullien19, Elena Karimova20, Sylvain Lanot21, Loïc Le Dantec22, Tristan Pascart23, Laurianne Plastaras24, Nathalie Sultan-Bichat25, Xavier Truchet26, Stéphane Varin27, Daniel Wendling28, Lousie Gaboriau29, Delphine Staumont-Sallé30, Laurent Peyrin-Biroulet31 and René-Marc Flipo1, 1Univ-Lille, CHU Lille, department of rheumatology, Lille, France, 2Univ-Lille, CHU Lille, department of gastroenterology, Lille, France, 3Aix Marseille Univ, APHM, department of rheumatology, Marseille, France, 4CHPG, department of rheumatology, Monaco, Monaco, 5AP-HP, Hôpital Pitié-Salpêtrière, Service de Rhumatologie, Paris, 75013, Paris, France, 6CHU de Nantes, department of dermatology, Nantes, France, 7CHRU Nancy, department of rheumatology, VANDOEUVRE LES NANCY, Lorraine, France, 8CHU Caen, department of rheumatology, Caen, France, 9Hôpital Henri Mondor, Université Paris Est Créteil, EA 7379 EpiDermE, department of rheumatology, Créteil, France, 10Hospital Pierre Paul Riquet, Toulouse, France, 11CH Le Mans, department of rheumatology, Le Mans, France, 12Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, France, 13CHU Grenoble, department of rheumatology, Grenoble, France, 14CHU Montpellier, department of rheumatology, Montpellier, France, 15CH La Rochelle, department of rheumatology, La Rochelle, France, 16CHU Tours, department of rheumatology, Tours, France, 17CH Saint-Brieuc, department of rheumatology, Saint-Brieuc, France, 18CHU Amiens, department of rheumatology, Amiens, France, 19CHU Lyon, department of dermatology, Lyon, France, 20CH Lens, department of dermatology, Lens, France, 21CH Alençon, department of rheumatology, Alençon, France, 22Ahnac, department of rheumatology, Hénin-Beaumont, France, 23Ghicl, Hôpital Saint-Philibert, department of rheumatology, Lomme, France, 24CH Colmar, department of gastroenterology, Colmar, France, 25CH Ouest-Réunion, department of dermatology, Saint Paul, La Réunion, France, 26HIA Sainte-Anne, department of gastroenterology, Toulon, France, 27CHD Vendée, department of rheumatology, La Roche-sur-Yon, France, 28CHU Besançon, department of rheumatology, Besancon, France, 29Univ-Lille, CHU Lille, department of pharmacovigilance, Lille, France, 30Univ-Lille, CHU Lille, department of dermatology, Lille, France, 31CHU Nancy, department of gastroenterology, VANDOEUVRE LES NANCY, Lorraine, France

    Background/Purpose: A warning regarding safety of Interleukin 17 inhibitors (IL-17i) has been issued from data of randomized controlled trials (RCT) showing cases of new-onset inflammatory bowel…
  • Abstract Number: 1875 • ACR Convergence 2020

    Heterogeneity Amongst Men and Women with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

    Zhixiu Li1, Muhammad Khan2, Mohammad Khan3, Peter Villiger4, Heinz Baumberger5, Hermine Zandwijk6, Sjef van der Linden7 and Matthew Brown8, 1Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, 2Case Western Reserve University, Cleveland OH, Westlake, OH, 3Kent State University, Kent, OH, 4Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, 5Retired, Flims, Tajikistan, 6Retired, Mortroux, Belgium, 7Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, 8Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom

    Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial disease (nr-axSpA). Our purpose was to investigate genetic heterogeneity of clinically diagnosed axSpA.Methods:…
  • Abstract Number: 0305 • ACR Convergence 2020

    A Delphi Consensus Study to Standardize Terminology for the Pre-clinical Phase of Psoriatic Arthritis

    Rebecca Haberman1, Lourdes Perez-Chada2, Vinod Chandran3, Cheryl Rosen4, Christopher Ritchlin5, Lihi Eder6, Philip Mease7, Soumya Reddy8, Alexis Ogdie9, Joseph Merola10 and Jose Scher1, 1NYU School of Medicine, New York City, 2Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Department of Medicine, University of Rochester Medical Center, Rochester, NY, 6Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, 7Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 8NYU School of Medicine, New York, NY, 9University of Pennsylvania, Philadelphia, PA, 10Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: The concept of prevention of psoriatic arthritis (PsA) has gained increased interest given the physical limitation and poor quality-of-life experienced by PsA patients coupled…
  • Abstract Number: 0867 • ACR Convergence 2020

    Hydroxychloroquine Use Predicts Significantly Higher Patient and Graft Survival in Post-Renal Transplant Lupus Nephritis Patients

    Shivani Garg1, Tripti Singh1, Sarah Panzer2 and Christie Bartels3, 1UW Madison, Madison, WI, 2UW-Madison, Madison, 3University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI

    Background/Purpose: Hydroxychloroquine (HCQ) is a pivotal therapy for lupus nephritis (LN) as it contributes to 65% lower mortality and 84% lower renal damage compared to…
  • Abstract Number: 1388 • ACR Convergence 2020

    A Systematic Assessment of Demographics, Clinical and Serological Features Associated with Colonic Hypomotility in Systemic Sclerosis

    Jenice Cheah1, Jamie Perin2, Elizabeth Volkmann3, Laura Hummers4, Fredrick Wigley5 and Zsuzsanna McMahan6, 1JHUSOM, Baltimore, 2JHUSPH, Baltimore, 3University of California, Los Angeles, Los Angeles, CA, 4Johns Hopkins Univerisity, Ellicott City, MD, 5Johns Hopkins University School of Medicine, Baltimore, MD, 6Johns Hopkins University, Baltimore

    Background/Purpose: Colonic dysmotility affects up to 50% of patients with systemic sclerosis (SSc). While some patients have mild colonic disease, others experience severe complications, such…
  • Abstract Number: 1945 • ACR Convergence 2020

    Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients with Giant Cell Arteritis

    Hussein Baalbaki1, Darya Jalaledin2, Catherine Lachance2 and Jean-Paul Makhzoum3, 1Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, 2Universite de Montreal, Montreal, QC, Canada, 3Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada

    Background/Purpose: Permanent vision loss (PVL) is a feared complication and a leading cause of morbidity in Giant Cell Arteritis (GCA). Multiple risk factors for ocular…
  • Abstract Number: 0433 • ACR Convergence 2020

    Racial Disparities and New SLE-Specific Predictors of Stroke and Ischemic Heart Disease in Patients with Lupus

    Shivani Garg1, Christie Bartels2, Gaobin Bao3, Cristina Drenkard4 and S. Sam Lim3, 1UW Madison, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, 3Emory University, Atlanta, GA, 4Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA

    Background/Purpose: In the US, cardiovascular disease (CVD) is the leading cause of disparities in life expectancy between black and white populations. We recently reported a…
  • Abstract Number: 0869 • ACR Convergence 2020

    Retinal Toxicity in a Multinational Inception Cohort of Systemic Lupus Patients on Hydroxychloroquine

    Celline Almeida-Brasil1, John Hanly2, Murray Urowitz3, Ann Clarke4, Rosalind Ramsey-Goldman5, Caroline Gordon6, Michelle Petri7, Ellen M Ginzler8, Daniel J Wallace9, Sang-Cheol Bae10, Juanita Romero-Díaz11, Mary Ann Dooley12, Christine A. Peschken13, David Isenberg14, Anisur Rahman14, Susan Manzi15, Søren Jacobsen16, S. Sam Lim17, Ronald Van Vollenhoven18, Ola Nived19, Andreas Jönsen19, Diane Kamen20, Cynthia Aranow21, Guillermo Ruiz-Irastorza22, Jorge Sanchez-Guerrero23, Dafna Gladman24, Paul Fortin25, Graciela Alarcón26, Joan Merrill27, Kenneth Kalunian28, Manuel Ramos-Casals29, Kristjan Steinsson30, Asad Zoma31, Anca Askanase32, Munther Khamashta33, Ian Bruce34, Murat Inanc35 and Sasha Bernatsky36, 1McGill University, Montreal, Canada, 2QEII Health Sciences Centre, Halifax, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada, 4University of Calgary, Calgary, Canada, 5Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 6University of Birmingham, Birmingham, England, United Kingdom, 7Johns Hopkins University School of Medicine, Baltimore, 8SUNY Downstate Health Sciences University, Brooklyn, 9Cedars-Sinai Medical Center, Beverly Hills, CA, 10Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 11Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 12UNC Health, Chapel Hil, 13University of Manitoba, Winnipeg, Canada, 14University College London, London, United Kingdom, 15Temple University, Philadelphia, 16University of Copenhagen, Copenhagen, Denmark, 17Emory University, Atlanta, GA, 18University of Amsterdam, Amsterdam, Netherlands, 19Lund University, Lund, Sweden, 20Medical University of South Carolina, Charleston, SC, 21Feinstein Institutes for Medical Research, Manhasset, NY, 22Hospital Universitario Cruces, Barakaldo, Spain, 23University of Toronto, Toronto, Canada, 24Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 25CHU de Quebec - Universite Laval, Quebec, Canada, 26Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, 27New York University, New York, 28University of California San Diego, La Jolla, CA, 29University of Barcelona, Barcelona, Spain, 30Reykjavik University, Reykjavik, Iceland, 31University of Glasgow, Glasgow, United Kingdom, 32Columbia University College of Physicians & Surgeons, New York, NY, 33King's College London, London, United Kingdom, 34The University of Manchester, Manchester, United Kingdom, 35Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 36The Research Institute of the McGill University Health Centre, Montreal, ON, Canada

    Background/Purpose: Despite the beneficial effects of hydroxychloroquine (HCQ) in systemic lupus erythematosus (SLE), retinal toxicity is a concern. Factors associated with retinal toxicity have been…
  • Abstract Number: 1436 • ACR Convergence 2020

    Incidence Rate, Predictors and Outcome of Stroke in Patients with ANCA Associated Vasculitis – A Population-based Study

    Dennis Tabakovic1, Rona Smith2, David Jayne3 and Aladdin Mohammad4, 1Lund University, Lund, Skane Lan, Sweden, 2University of Cambridge, Cambridge, United Kingdom, 3Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, 4Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden

    Background/Purpose: To study the incidence rate, predictors and outcome of stroke in patients with ANCA-associated vasculitis (AAV) within a defined population in southern Sweden.Methods: The…
  • Abstract Number: 1978 • ACR Convergence 2020

    Prevalence and Factors Associated with Patient-Physician Discordance Among RA Patients Initiating Advanced Therapy

    Jeffrey Curtis1, Rose Medeiros2, I-Heng Lee3, Rachel Mackey4, Richard Haubrich3, Hao Hu5, Jeffrey Greenberg6 and Alicea Wu3, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Corrona, LLC, Waltham, MA, 3Gilead Sciences, Foster City, CA, 4Corrona, LLC and University of Pittsburgh, Waltham, MA, 5Gilead Sciences, Inc., Foster City, CA, 6Corrona, LLC and NYU School of Medicine, Waltham, MA

    Background/Purpose: Some rheumatoid arthritis (RA) patients rate their disease activity worse than their physician does, but recent prevalence and factors associated with such discordance have…
  • Abstract Number: 465 • 2019 ACR/ARP Annual Meeting

    Prognostic Factors and Clinical Outcome Modifiers in Patients with Rheumatoid Arthritis: A Review

    Leticia Ferri1, Grace Crocket 2, Xue Han 1, Boris Breznen 3 and Mir Sohail Fazeli 3, 1Bristol-Myers Squibb Company, Princeton, NJ, 2Bristol-Myers Squibb; Rutgers University, New York City, NY, 3Doctor Evidence, Santa Monica, CA

    Background/Purpose: The current goal in treatment of RA is to deliver therapies tailored to individual patients’ characteristics. Establishing disease prognosis is a crucial first step…
  • Abstract Number: 2327 • 2019 ACR/ARP Annual Meeting

    Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors and the Role of Auto-antibodies

    Leticia Ferri1, Grace Crocket 2, Yuting Kuang 3, Boris Breznen 4 and Mir Sohail Fazeli 4, 1Bristol-Myers Squibb Company, Princeton, NJ, 2Bristol-Myers Squibb; Rutgers University, New York City, NY, 3Doctor Evidence, Doctor Evidence, CA, 4Doctor Evidence, Santa Monica, CA

    Background/Purpose: Shorter life expectancy in RA patients has in part been associated with an increased incidence of cardiovascular disease (CVD). This literature review summarizes the…
  • Abstract Number: 2349 • 2019 ACR/ARP Annual Meeting

    Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review

    Xue Han1, Leticia Ferri 1, Grace Crocket 2, Sophie Yoon 3, Tracy Slanger 3 and Mir Sohail Fazeli 3, 1Bristol-Myers Squibb Company, Princeton, NJ, 2Bristol-Myers Squibb; Rutgers University, New York City, NY, 3Doctor Evidence, Santa Monica, CA

    Background/Purpose: Interstitial lung disease (ILD) is the most common lung manifestation of RA and the 2nd leading cause of death in RA patients.1,2 The purpose…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences